IRADIMED CORP (IRMD) Stock Fundamental Analysis
USA - NASDAQ:IRMD - US46266A1097 - Common Stock
85.42 USD
+1.07 (+1.27%)
85.42 USD
0 (0%)
Overall IRMD gets a fundamental rating of 7 out of 10. We evaluated IRMD against 188 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IRMD a very profitable company, without any liquidiy or solvency issues. IRMD has a correct valuation and a medium growth rate. This makes IRMD very considerable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year IRMD was profitable.
IRMD had a positive operating cash flow in the past year.
In the past 5 years IRMD has always been profitable.
IRMD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
IRMD has a Return On Assets of 18.47%. This is amongst the best in the industry. IRMD outperforms 98.40% of its industry peers.
IRMD has a Return On Equity of 21.54%. This is amongst the best in the industry. IRMD outperforms 94.15% of its industry peers.
With an excellent Return On Invested Capital value of 19.30%, IRMD belongs to the best of the industry, outperforming 97.34% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for IRMD is significantly above the industry average of 8.98%.
The last Return On Invested Capital (19.30%) for IRMD is above the 3 year average (18.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.47% | ||
| ROE | 21.54% | ||
| ROIC | 19.3% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
IRMD has a Profit Margin of 26.31%. This is amongst the best in the industry. IRMD outperforms 94.68% of its industry peers.
In the last couple of years the Profit Margin of IRMD has remained more or less at the same level.
The Operating Margin of IRMD (30.87%) is better than 97.87% of its industry peers.
IRMD's Operating Margin has improved in the last couple of years.
IRMD has a Gross Margin of 77.07%. This is amongst the best in the industry. IRMD outperforms 89.89% of its industry peers.
In the last couple of years the Gross Margin of IRMD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.87% | ||
| PM (TTM) | 26.31% | ||
| GM | 77.07% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IRMD is creating value.
Compared to 1 year ago, IRMD has more shares outstanding
The number of shares outstanding for IRMD has been increased compared to 5 years ago.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 42.31 indicates that IRMD is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 42.31, IRMD belongs to the top of the industry, outperforming 99.47% of the companies in the same industry.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 42.31 |
ROIC/WACC2.2
WACC8.78%
2.3 Liquidity
A Current Ratio of 6.64 indicates that IRMD has no problem at all paying its short term obligations.
IRMD has a Current ratio of 6.64. This is amongst the best in the industry. IRMD outperforms 84.04% of its industry peers.
A Quick Ratio of 5.72 indicates that IRMD has no problem at all paying its short term obligations.
IRMD's Quick ratio of 5.72 is amongst the best of the industry. IRMD outperforms 85.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.64 | ||
| Quick Ratio | 5.72 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.75% over the past year.
Measured over the past years, IRMD shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.92% on average per year.
IRMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.91%.
Measured over the past years, IRMD shows a quite strong growth in Revenue. The Revenue has been growing by 13.71% on average per year.
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
Revenue 1Y (TTM)12.91%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.69%
3.2 Future
The Earnings Per Share is expected to grow by 9.26% on average over the next years. This is quite good.
Based on estimates for the next years, IRMD will show a quite strong growth in Revenue. The Revenue will grow by 8.97% on average per year.
EPS Next Y12.51%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue Next Year11.05%
Revenue Next 2Y11.16%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 46.93 indicates a quite expensive valuation of IRMD.
Based on the Price/Earnings ratio, IRMD is valued a bit cheaper than the industry average as 69.15% of the companies are valued more expensively.
IRMD is valuated expensively when we compare the Price/Earnings ratio to 25.56, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 39.97, IRMD can be considered very expensive at the moment.
70.21% of the companies in the same industry are more expensive than IRMD, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of IRMD to the average of the S&P500 Index (34.62), we can say IRMD is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.93 | ||
| Fwd PE | 39.97 |
4.2 Price Multiples
68.09% of the companies in the same industry are more expensive than IRMD, based on the Enterprise Value to EBITDA ratio.
69.68% of the companies in the same industry are more expensive than IRMD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 77.89 | ||
| EV/EBITDA | 39.34 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of IRMD may justify a higher PE ratio.
PEG (NY)3.75
PEG (5Y)3.37
EPS Next 2Y13.8%
EPS Next 3Y9.26%
5. Dividend
5.1 Amount
IRMD has a yearly dividend return of 0.80%, which is pretty low.
Compared to an average industry Dividend Yield of 1.69, IRMD pays a better dividend. On top of this IRMD pays more dividend than 92.02% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, IRMD's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.8% |
5.2 History
IRMD has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
39.59% of the earnings are spent on dividend by IRMD. This is a low number and sustainable payout ratio.
DP39.59%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
85.42
+1.07 (+1.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners59.43%
Inst Owner Change-1.64%
Ins Owners36.81%
Ins Owner Change-5.49%
Market Cap1.09B
Revenue(TTM)80.51M
Net Income(TTM)21.18M
Analysts82.5
Price Target76.5 (-10.44%)
Short Float %1.99%
Short Ratio3.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.8% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.59%
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.85%
Min EPS beat(2)1.27%
Max EPS beat(2)10.44%
EPS beat(4)3
Avg EPS beat(4)2.54%
Min EPS beat(4)-1.96%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)4.28%
EPS beat(12)10
Avg EPS beat(12)6.04%
EPS beat(16)14
Avg EPS beat(16)9.77%
Revenue beat(2)2
Avg Revenue beat(2)0.71%
Min Revenue beat(2)0.01%
Max Revenue beat(2)1.41%
Revenue beat(4)2
Avg Revenue beat(4)-0.08%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)1.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.25%
Revenue beat(12)6
Avg Revenue beat(12)-0.02%
Revenue beat(16)7
Avg Revenue beat(16)-0.16%
PT rev (1m)2.04%
PT rev (3m)2.04%
EPS NQ rev (1m)2.13%
EPS NQ rev (3m)-2.04%
EPS NY rev (1m)-1.62%
EPS NY rev (3m)4.9%
Revenue NQ rev (1m)5.37%
Revenue NQ rev (3m)1.27%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)2.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.93 | ||
| Fwd PE | 39.97 | ||
| P/S | 13.5 | ||
| P/FCF | 77.89 | ||
| P/OCF | 43.44 | ||
| P/B | 11.05 | ||
| P/tB | 11.44 | ||
| EV/EBITDA | 39.34 |
EPS(TTM)1.82
EY2.13%
EPS(NY)2.14
Fwd EY2.5%
FCF(TTM)1.1
FCFY1.28%
OCF(TTM)1.97
OCFY2.3%
SpS6.33
BVpS7.73
TBVpS7.47
PEG (NY)3.75
PEG (5Y)3.37
Graham Number17.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.47% | ||
| ROE | 21.54% | ||
| ROCE | 24.38% | ||
| ROIC | 19.3% | ||
| ROICexc | 43.34% | ||
| ROICexgc | 46.82% | ||
| OM | 30.87% | ||
| PM (TTM) | 26.31% | ||
| GM | 77.07% | ||
| FCFM | 17.33% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexgc growth 3Y-6.9%
ROICexgc growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score4
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1128.47% | ||
| Cap/Sales | 13.74% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 96.82% | ||
| Profit Quality | 65.85% | ||
| Current Ratio | 6.64 | ||
| Quick Ratio | 5.72 | ||
| Altman-Z | 42.31 |
F-Score4
WACC8.78%
ROIC/WACC2.2
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
EPS Next Y12.51%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue 1Y (TTM)12.91%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.69%
Revenue Next Year11.05%
Revenue Next 2Y11.16%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
EBIT growth 1Y16.55%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y194.31%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y98.66%
OCF growth 3Y31.53%
OCF growth 5Y20.16%
IRADIMED CORP / IRMD FAQ
Can you provide the ChartMill fundamental rating for IRADIMED CORP?
ChartMill assigns a fundamental rating of 7 / 10 to IRMD.
What is the valuation status of IRADIMED CORP (IRMD) stock?
ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.
Can you provide the profitability details for IRADIMED CORP?
IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.
How financially healthy is IRADIMED CORP?
The financial health rating of IRADIMED CORP (IRMD) is 9 / 10.
Is the dividend of IRADIMED CORP sustainable?
The dividend rating of IRADIMED CORP (IRMD) is 3 / 10 and the dividend payout ratio is 39.59%.